ClinicalTrials.gg
CompletedNCT04537923SURPASS-6Updated Nov 2, 2023Results posted

A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin

A Phase 3 interventional study of Tirzepatide and Insulin Lispro (U100) in Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 135 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-02.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,428
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 — 7 open to participants now, 13 under way, 2 of them phase 3. Tirzepatide · Diabetes Mellitus, Type 2.

Enrollment
5th of 43
1,428 · median 160
Started
2020
with 4 others
Phase 3
17 of 43
1 open now
Registered
18th of 43
by date
Lead sponsor
31 of 43
Eli Lilly and Company

Among the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, this one is the 5th largest by enrollment, is one of 5 that started in 2020, is one of 17 in phase 3, and was the 18th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About tirzepatide

Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to insulin lispro (U100) three times a day in participants with type 2 diabetes that are already on insulin glargine (U100), with or without metformin.

03

Conditions studied

  • Type 2 Diabetes

Keywords

  • glucose-dependent insulinotropic polypeptide (GIP)
  • glucagon-like peptide-1 (GLP-1)
  • GIP/GLP-1 dual receptor agonist
  • T2DM
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have been diagnosed with type 2 diabetes mellitus (T2DM)
  • Have between ≥7.5% and ≤11%
  • Have been treated for at least 90 days prior to day of screening with once or twice daily basal insulin with or without stable dose of metformin ≥1500 mg/day and up to maximum approved dose per country specific approved label, sulfonylureas or dipeptidyl peptidase 4 inhibitors
  • Be of stable weight (± 5%) for at least 90 days
  • Have a ≥23 kilograms per meter squared (kg/m²) and ≤45 kg/m² at screening

Exclusion criteria

Exclusion Criteria

  • Have type 1 diabetes mellitus
  • Have had chronic or acute pancreatitis any time prior to study entry
  • Have proliferative diabetic retinopathy or diabetic macular edema or nonproliferative diabetic retinopathy requiring immediate or urgent treatment
  • Have disorders associated with slowed emptying of the stomach, have had any stomach surgeries for the purpose of weight loss, or are chronically taking drugs that directly affect gastrointestinal motility
  • Have had a heart attack, stroke, or hospitalization for congestive heart failure in the past 2 months
  • Have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2
  • Have been taking weight loss drugs, including over-the-counter medications during the last 3 months
  • Have an estimated \<30 mL/minute/1.73 m² [for participants on metformin, estimated glomerular filtration rate \<45 mL/min/1.73 m2 (or lower than the country-specific threshold for using the protocol-required dose of metformin per local label)]
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,428 participants (actual)

Study arms

  • Experimental
    5 mg Tirzepatide

    5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.

    Drug: Tirzepatide

  • Experimental
    10 mg Tirzepatide

    10 mg tirzepatide administered SC once a week.

    Drug: Tirzepatide

  • Experimental
    15 mg Tirzepatide

    15 mg tirzepatide administered SC once a week.

    Drug: Tirzepatide

  • Active comparator
    Insulin Lispro

    Insulin lispro 100 units per milliliter (U100) administered SC three times a day.

    Drug: Insulin Lispro (U100)

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg)

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with covariates Baseline + Pooled Country + Baseline Metformin Use (Yes, No) + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, Week 52

Secondary outcomes

  1. Change From Baseline in HbA1c

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. LS mean was determined by MMRM model with covariates Baseline + Pooled Country + Baseline Metformin Use (Yes, No) + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, Week 52

  2. Percentage of Participants With HbA1c Target Values <7.0%

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.

    Time frame: Week 52

  3. Change From Baseline in Body Weight

    LS mean was determined by MMRM model with Baseline + Pooled Country + Baseline Metformin Use (Yes, No) + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, Week 52

  4. Change From Baseline in Fasting Serum Glucose

    LS mean was determined by MMRM model with variables Baseline + Pooled Country + Baseline metformin Use (Yes, No) + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, Week 52

  5. Change From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG) Values

    The self-monitored plasma glucose (SMBG) data were collected at the following 7 time points: Morning Premeal - Fasting, Morning 2-hour Post meal, Midday Premeal, Midday 2-hour Post meal, Evening Premeal, Evening 2-hour Post meal and Bedtime. The daily average was calculated as the average of the 7 blood glucose values collected on a particular day. LS mean was determined by MMRM model with variables Baseline + Pooled Country + Baseline Metformin Use (Yes, No) + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, Week 52

  6. Percentage of Participants Who Achieved HbA1c Target Value of <7.0% Without Hypoglycemia

    Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.

    Time frame: Week 52

  7. Percentage of Participants Who Achieved Weight Loss ≥5%

    Percentage of Participants who Achieved Weight Loss ≥5% is reported here.

    Time frame: Week 52

  8. Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score

    The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and two overall summary scores: physical component summary (PCS) and mental component summary (MCS) scores. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. PCS score is reported here. PCS domain is scored by summing individual items and transforming scores into a 0 to 100 scale with higher scores indicating better health status or functioning. LS mean was determined by analysis of covariance (ANCOVA) model with variables Baseline + Pooled Country + Baseline Metformin Use (Yes, No) + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment (Type III sum of squares).

    Time frame: Baseline, Week 52

  9. Change From Baseline in 36-Item SF-36 Mental Component Summary (MCS) Score

    The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and two overall summary scores: physical component summary (PCS) and mental component summary (MCS) scores. MCS consisted of social functioning, vitality, mental health, and role-emotional scales. MCS score is reported here. MCS domain is scored by summing individual items and transforming scores into a 0 to 100 scale with higher scores indicating better health status or functioning. LS mean was determined by ANCOVA model with variables Baseline + Pooled Country + Baseline Metformin Use (Yes, No) + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment (Type III sum of squares).

    Time frame: Baseline, Week 52

07

Results

Posted Nov 2, 2023

Participant flow

Participant flow — Overall Study
Milestone5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin Lispro
Started243238236711
Received at least one dose of study drug243238236708
Completed228228225623
Not completed15101188
Withdrew: Adverse event2124
Withdrew: Death33111
Withdrew: Lost to follow-up1216
Withdrew: Physician decision1025
Withdrew: Pregnancy1000
Withdrew: Withdrawal by subject44458
Withdrew: Missed study visits2003
Withdrew: Sponsor's decision0011
Withdrew: Safety reasons1000

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg)

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with covariates Baseline + Pooled Country + Baseline Metformin Use (Yes, No) + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Percentage of HbA1c
Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg)
Percentage of HbA1cPooled 5 mg/10 mg/15 mg TirzepatideInsulin Lispro
Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg)-2.26 ± 0.048-1.16 ± 0.049
Statistical analysis
  • Pooled 5 mg/10 mg/15 mg Tirzepatide vs Insulin Lispro · Mixed Models Analysis · p = <0.001 · Ls mean difference: -1.10 · 95% CI -1.24 to -0.97
SecondaryChange From Baseline in HbA1c

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. LS mean was determined by MMRM model with covariates Baseline + Pooled Country + Baseline Metformin Use (Yes, No) + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Percentage of HbA1c
Change From Baseline in HbA1c
Percentage of HbA1c5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin Lispro
Change From Baseline in HbA1c-2.05 ± 0.082-2.27 ± 0.083-2.46 ± 0.084-1.16 ± 0.049
Statistical analysis
  • 5 mg Tirzepatide vs Insulin Lispro · Mixed Models Analysis · p = <0.001 · Ls mean difference: -0.89 · 95% CI -1.08 to -0.70
  • 10 mg Tirzepatide vs Insulin Lispro · Mixed Models Analysis · p = <0.001 · Ls mean difference: -1.11 · 95% CI -1.30 to -0.92
  • 15 mg Tirzepatide vs Insulin Lispro · Mixed Models Analysis · p = <0.001 · Ls mean difference: -1.30 · 95% CI -1.49 to -1.11
SecondaryPercentage of Participants With HbA1c Target Values <7.0%

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With HbA1c Target Values <7.0%
Percentage of participants5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin Lispro
Percentage of Participants With HbA1c Target Values <7.0%61.0475.6479.8636.69
Statistical analysis
  • 5 mg Tirzepatide vs Insulin Lispro · Regression, Logistic · p = <0.0001 · Odds ratio (or): 3.13 · 95% CI 2.25 to 4.36
  • 10 mg Tirzepatide vs Insulin Lispro · Regression, Logistic · p = <0.0001 · Odds ratio (or): 6.16 · 95% CI 4.27 to 8.88
  • 15 mg Tirzepatide vs Insulin Lispro · Regression, Logistic · p = <0.0001 · Odds ratio (or): 7.94 · 95% CI 5.37 to 11.75
SecondaryChange From Baseline in Body Weight

LS mean was determined by MMRM model with Baseline + Pooled Country + Baseline Metformin Use (Yes, No) + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Kilograms (kg)
Change From Baseline in Body Weight
Kilograms (kg)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin Lispro
Change From Baseline in Body Weight-6.9 ± 0.37-9.9 ± 0.37-12.0 ± 0.383.8 ± 0.22
Statistical analysis
  • 5 mg Tirzepatide vs Insulin Lispro · Mixed Models Analysis · p = <0.001 · Ls mean difference: -10.7 · 95% CI -11.5 to -9.9
  • 10 mg Tirzepatide vs Insulin Lispro · Mixed Models Analysis · p = <0.001 · Ls mean difference: -13.7 · 95% CI -14.5 to -12.9
  • 15 mg Tirzepatide vs Insulin Lispro · Mixed Models Analysis · p = <0.001 · Ls mean difference: -15.9 · 95% CI -16.7 to -15.0
SecondaryChange From Baseline in Fasting Serum Glucose

LS mean was determined by MMRM model with variables Baseline + Pooled Country + Baseline metformin Use (Yes, No) + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · milligram per Deciliter (mg/dL)
Change From Baseline in Fasting Serum Glucose
milligram per Deciliter (mg/dL)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin Lispro
Change From Baseline in Fasting Serum Glucose-33.2 ± 3.28-43.0 ± 3.32-41.6 ± 3.42-10.0 ± 1.99
Statistical analysis
  • 5 mg Tirzepatide vs Insulin Lispro · Mixed Models Analysis · p = <0.001 · Ls mean difference: -23.2 · 95% CI -30.8 to -15.7
  • 10 mg Tirzepatide vs Insulin Lispro · Mixed Models Analysis · p = <0.001 · Ls mean difference: -33.0 · 95% CI -40.6 to -25.4
  • 15 mg Tirzepatide vs Insulin Lispro · Mixed Models Analysis · p = <0.001 · Ls mean difference: -31.6 · 95% CI -39.3 to -23.8
SecondaryChange From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG) Values

The self-monitored plasma glucose (SMBG) data were collected at the following 7 time points: Morning Premeal - Fasting, Morning 2-hour Post meal, Midday Premeal, Midday 2-hour Post meal, Evening Premeal, Evening 2-hour Post meal and Bedtime. The daily average was calculated as the average of the 7 blood glucose values collected on a particular day. LS mean was determined by MMRM model with variables Baseline + Pooled Country + Baseline Metformin Use (Yes, No) + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · mg/dL/day
Change From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG) Values
mg/dL/day5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin Lispro
Change From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG) Values-56.7 ± 1.80-61.5 ± 1.8567.6 ± 1.86-55.8 ± 1.13
Statistical analysis
  • 5 mg Tirzepatide vs Insulin Lispro · Mixed Models Analysis · p = 0.682 · Ls mean difference: -0.9 · 95% CI -5.0 to 3.3
  • 10 mg Tirzepatide vs Insulin Lispro · Mixed Models Analysis · p = 0.010 · Ls mean difference: -5.6 · 95% CI -9.9 to -1.4
  • 15 mg Tirzepatide vs Insulin Lispro · Mixed Models Analysis · p = <0.001 · Ls mean difference: -11.8 · 95% CI -16.0 to -7.5
SecondaryPercentage of Participants Who Achieved HbA1c Target Value of <7.0% Without Hypoglycemia

Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved HbA1c Target Value of <7.0% Without Hypoglycemia
Percentage of participants5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin Lispro
Percentage of Participants Who Achieved HbA1c Target Value of <7.0% Without Hypoglycemia52.7070.0575.1213.41
Statistical analysis
  • 5 mg Tirzepatide vs Insulin Lispro · Regression, Logistic · p = <0.001 · Odds ratio (or): 8.19 · 95% CI 5.66 to 11.83
  • 10 mg Tirzepatide vs Insulin Lispro · Regression, Logistic · p = <0.001 · Odds ratio (or): 16.90 · 95% CI 11.44 to 24.96
  • 15 mg Tirzepatide vs Insulin Lispro · Regression, Logistic · p = <0.001 · Odds ratio (or): 21.85 · 95% CI 14.49 to 32.93
SecondaryPercentage of Participants Who Achieved Weight Loss ≥5%

Percentage of Participants who Achieved Weight Loss ≥5% is reported here.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Weight Loss ≥5%
Percentage of participants5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin Lispro
Percentage of Participants Who Achieved Weight Loss ≥5%64.1979.2183.156.34
Statistical analysis
  • 5 mg Tirzepatide vs Insulin Lispro · Regression, Logistic · p = <0.001 · Odds ratio (or): 28.25 · 95% CI 18.36 to 43.46
  • 10 mg Tirzepatide vs Insulin Lispro · Regression, Logistic · p = <0.001 · Odds ratio (or): 58.90 · 95% CI 36.76 to 94.39
  • 15 mg Tirzepatide vs Insulin Lispro · Regression, Logistic · p = <0.001 · Odds ratio (or): 77.76 · 95% CI 47.49 to 127.33
SecondaryChange From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score

The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and two overall summary scores: physical component summary (PCS) and mental component summary (MCS) scores. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. PCS score is reported here. PCS domain is scored by summing individual items and transforming scores into a 0 to 100 scale with higher scores indicating better health status or functioning. LS mean was determined by analysis of covariance (ANCOVA) model with variables Baseline + Pooled Country + Baseline Metformin Use (Yes, No) + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment (Type III sum of squares).

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score
score on a scale5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin Lispro
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score1.0 ± 0.461.7 ± 0.461.7 ± 0.48-0.6 ± 0.28
Statistical analysis
  • 5 mg Tirzepatide vs Insulin Lispro · ANCOVA · p = 0.005 · Ls mean difference: 1.5 · 95% CI 0.5 to 2.6
  • 10 mg Tirzepatide vs Insulin Lispro · ANCOVA · p = <0.001 · Ls mean difference: 2.3 · 95% CI 1.2 to 3.3
  • 15 mg Tirzepatide vs Insulin Lispro · ANCOVA · p = <0.001 · Ls mean difference: 2.2 · 95% CI 1.2 to 3.3
SecondaryChange From Baseline in 36-Item SF-36 Mental Component Summary (MCS) Score

The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and two overall summary scores: physical component summary (PCS) and mental component summary (MCS) scores. MCS consisted of social functioning, vitality, mental health, and role-emotional scales. MCS score is reported here. MCS domain is scored by summing individual items and transforming scores into a 0 to 100 scale with higher scores indicating better health status or functioning. LS mean was determined by ANCOVA model with variables Baseline + Pooled Country + Baseline Metformin Use (Yes, No) + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment (Type III sum of squares).

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in 36-Item SF-36 Mental Component Summary (MCS) Score
score on a scale5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin Lispro
Change From Baseline in 36-Item SF-36 Mental Component Summary (MCS) Score0.3 ± 0.591.5 ± 0.590.7 ± 0.62-1.3 ± 0.36
Statistical analysis
  • 5 mg Tirzepatide vs Insulin Lispro · ANCOVA · p = 0.020 · Ls mean difference: 1.6 · 95% CI 0.3 to 2.9
  • 10 mg Tirzepatide vs Insulin Lispro · ANCOVA · p = <0.001 · Ls mean difference: 2.8 · 95% CI 1.5 to 4.2
  • 15 mg Tirzepatide vs Insulin Lispro · ANCOVA · p = 0.004 · Ls mean difference: 2.1 · 95% CI 0.7 to 3.5

Adverse events

Collected over Baseline up to week 56. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
5 mg Tirzepatide3/243 (1.2%)20/243 (8.2%)94/243 (38.7%)
10 mg Tirzepatide3/238 (1.3%)16/238 (6.7%)116/238 (48.7%)
15 mg Tirzepatide1/236 (0.4%)17/236 (7.2%)121/236 (51.3%)
Insulin Lispro11/708 (1.6%)81/708 (11.4%)99/708 (14%)
Most frequent serious events
Showing 10 of 84
Most frequent serious events
Event5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin Lispro
HypoglycaemiaMetabolism and nutrition disorders2/2433/2381/23628/708
Covid-19Infections and infestations1/2431/2382/2367/708
Covid-19 pneumoniaInfections and infestations2/2432/2382/2367/708
PneumoniaInfections and infestations1/2431/2382/2360/708
Ischaemic strokeNervous system disorders0/2431/2382/2361/708
Acute myocardial infarctionCardiac disorders0/2432/2380/2362/708
ErysipelasInfections and infestations2/2430/2380/2360/708
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/1440/1490/1330/396
Acute coronary syndromeCardiac disorders0/2430/2381/2360/708
Angina unstableCardiac disorders0/2430/2381/2363/708
Most frequent other events
Most frequent other events
Event5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin Lispro
NauseaGastrointestinal disorders33/24349/23861/2368/708
Decreased appetiteMetabolism and nutrition disorders20/24328/23840/2361/708
DiarrhoeaGastrointestinal disorders29/24336/23826/23617/708
VomitingGastrointestinal disorders11/24321/23830/2364/708
Covid-19Infections and infestations28/24319/23821/23672/708
DyspepsiaGastrointestinal disorders15/24327/23827/2364/708
ConstipationGastrointestinal disorders6/2438/23814/2364/708

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin LisproTotal
Mean58.00 ± 10.1859.60 ± 9.4158.20 ± 9.6259.00 ± 9.7458.80 ± 9.75
Sex: Female, Male
Sex: Female, Male(Participants)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin LisproTotal
Female144149133398824
Male9989103313604
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin LisproTotal
Hispanic or Latino148142149446885
Not Hispanic or Latino959387261536
Unknown or Not Reported03047
Race (NIH/OMB)
Race (NIH/OMB)(Participants)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin LisproTotal
American Indian or Alaska Native00123
Asian20248
Native Hawaiian or Other Pacific Islander00000
Black or African American119112657
White2302242206711345
More than one race052815
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin LisproTotal
Argentina707070207417
Belgium01012
Brazil474746141281
Czechia10992957
Germany7882447
Greece222915
Hungary442919
Italy12126
Mexico19202059118
Romania1414123878
Russia19171952107
Slovakia1613153983
Spain5331425
Turkey10124
United States28282885169
Hemoglobin A1c
Hemoglobin A1c(Percentage of HbA1c)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin LisproTotal
Mean8.89 ± 0.978.78 ± 0.988.74 ± 1.018.81 ± 0.968.80 ± 0.97
08

Study locations

135 sites
  • Syed Research Consultants Llc
    Sheffield, Alabama 35660, United States
  • Valley Research
    Fresno, California 93720, United States
  • National Research Institute - Huntington Park
    Huntington Park, California 90255, United States
  • National Research Institute - Huntington Park
    Los Angeles, California 90057, United States
  • Valley Clinical Trials, Inc.
    Northridge, California 91325, United States
  • National Research Institute - Huntington Park
    Panorama City, California 91402, United States
  • National Research Institute (NRI) - Santa Ana
    Santa Ana, California 92704, United States
  • Encompass Clinical Research
    Spring Valley, California 91978, United States
  • University Clinical Investigators, Inc.
    Tustin, California 92780, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • Excel Medical Clinical Trials
    Boca Raton, Florida 33434, United States
  • I R & Health Center, Inc.
    Hialeah, Florida 33012, United States
  • Sun Coast Clinical Research, Inc
    New Port Richey, Florida 34652, United States
  • South Broward Research
    Pembroke Pines, Florida 33027, United States
  • Metabolic Research Institute, Inc.
    West Palm Beach, Florida 33401, United States
  • Rocky Mountain Clinical Research
    Idaho Falls, Idaho 83404, United States
  • J H. Stroger Hosp of Cook Co
    Chicago, Illinois 60612, United States
  • Prairie Education and Research Cooperative
    Springfield, Illinois 62711, United States
  • Iowa Diabetes and Endocrinology Research Center
    West Des Moines, Iowa 50265, United States
  • Capital Diabetes and Endocrine Associates
    Camp Springs, Maryland 20746, United States
  • MedStar Health Research Institute
    Hyattsville, Maryland 20782, United States
  • Endocrine and Metabolic Consultants
    Rockville, Maryland 20852, United States
  • Glacier View Research Institute - Endocrinology
    Kalispell, Montana 59901, United States
  • Southern Nh Diabetes and Endocrinology
    Nashua, New Hampshire 03060, United States
  • Albany Medical College
    Albany, New York 12203, United States
  • PMG Research of Wilmington
    Wilmington, North Carolina 28401, United States
  • Intend Research, LLC
    Norman, Oklahoma 73069, United States
  • Heritage Valley Medical Group, Inc.
    Beaver, Pennsylvania 15009, United States
  • Preferred Primary Care Physicians
    Uniontown, Pennsylvania 15401, United States
  • Tribe Clinical Research, LLC
    Greenville, South Carolina 29607, United States
  • Dallas Diabetes Research Center
    Dallas, Texas 75230, United States
  • Diabetes and Thyroid Center of Fort Worth
    Fort Worth, Texas 76132, United States
  • Juno Research
    Houston, Texas 77040, United States
  • Biopharma Informatic, LLC
    Houston, Texas 77084, United States
  • North Hills Medical Research
    North Richland Hills, Texas 76180, United States
  • Texas Diabetes & Endocrinology, P.A.
    Round Rock, Texas 78681, United States
  • Clinical Trials of Texas, Inc.
    San Antonio, Texas 78229, United States
  • Consano Clinical Research, LLC
    Shavano Park, Texas 78231, United States
  • Martin Diagnostic Clinic
    Tomball, Texas 77375, United States
  • Rainier Clinical Research Center
    Renton, Washington 98057, United States
  • Centro Médico Viamonte
    Caba, Buenos Aires C1120AAC, Argentina
  • Investigaciones Medicas Imoba Srl
    Caba, Buenos Aires C1179AAB, Argentina
  • Instituto Centenario
    Caba, Buenos Aires C1204AAD, Argentina
  • Instituto de Investigaciones Clínicas Rosario (IIC-Rosario)- Sanatorio Delta
    Rosario, Buenos Aires S2000BIF, Argentina
  • CIPADI
    Godoy Cruz, Mendoza M5501ARP, Argentina
  • Instituto Médico Catamarca
    Rosario, Santa Fe 2000, Argentina
  • Instituto Médico Especializado (IME)
    Buenos Aires, 1405, Argentina
  • Asociación de Beneficencia Hospital Sirio Libanés
    Buenos Aires, C1419AHN, Argentina
  • CENUDIAB
    Ciudad Autónoma de Buenos Aire, C1440AAD, Argentina
  • Centro Diabetologico Dr Waitman
    Cordoba, 5000, Argentina
  • Centro Medico Privado San Vicente Diabetes
    Cordoba, X5006CBI, Argentina
  • Sanatorio Parque
    Salta, 4400, Argentina
  • AZ Damiaan Oostende
    Oostende, 8400, Belgium
  • Centro de Pesq. em Diabetes e Doencas Endocrino Metabol.
    Fortaleza, Ceará 60430-350, Brazil
  • CEDOES
    Vitoria, ES 29055-450, Brazil
  • Cline Research Center
    Curitiba, Paraná 80030, Brazil
  • QUANTA - Medicina Nuclear Alto da XV
    Curitiba, Paraná 80045-170, Brazil
  • Centro de Pesquisas em Diabetes
    Porto Alegre, Rio Grande Do Sul 90430-001, Brazil
  • CPCLIN
    São Paulo, SP 01228-200, Brazil
  • Hospital PUC-CAMPINAS
    Campinas, São Paulo 13060-904, Brazil
  • CECIP - Centro de Estudos do Interior Paulista
    Jaú, São Paulo 17201-130, Brazil
  • CEMEC - Centro Multidisciplinar de Estudos Clinicos EPP Ltda
    São Bernardo do Campo, São Paulo 09715-090, Brazil
  • ISPEM - Instituto São José dos Campos em Pesquisas Médicas
    São José dos Campos, São Paulo 12243-280, Brazil
  • Instituto Brasil de Pesquisa Clínica - IBPCLIN
    Rio de Janeiro, 20241180, Brazil
  • IPEC - Instituto de Pesquisa Clínica
    São Paulo, 01223-001, Brazil
  • CPQuali Pesquisa Clínica
    São Paulo, 01228-000, Brazil
  • BR Trials - Ensaios Clínicos e Consultoria Ltda
    São Paulo, 03325-050, Brazil
  • CEPIC - Centro Paulista de Investigação Clínica
    São Paulo, 04266-010, Brazil
  • Diabetologicka ordinace pro dospele
    Krnov, Moravskoslezský Kraj 79401, Czechia
  • Diabetologicka a obezitologicka ambulance
    Ceske Budejovice, 370 11, Czechia
  • Diahelp s.r.o., Interni a diabetologicka ambulance
    Pardubice, 530 02, Czechia
  • ResTrial s.r.o.
    Praha 8, 181 00, Czechia
  • Schwerpunktpraxis für Diabetes
    Hof, Bavaria 95030, Germany
  • InnoDiab Forschung Gmbh
    Essen, Nordrhein-Westfalen 45136, Germany
  • Medizentrum Essen-Borbeck
    Essen, Nordrhein-Westfalen 45355, Germany
  • Zentrum für klinische Studien
    Saint Ingbert, Saarland 66386, Germany
  • RED-Institut GmbH
    Oldenburg, Schleswig-Holstein 23758, Germany
  • MVZ im Altstadt-Carree Fulda GmbH
    Fulda, 36037, Germany
  • Diabetologische Schwerpunktpraxis Harburg
    Hamburg, 21073, Germany
  • Diabeteszentrum Hamburg West
    Hamburg, 22607, Germany
  • Gemeinschaftspraxis Dr. med. Josef und Wilma Großkopf
    Wallerfing, 94574, Germany
  • Iatriko Palaiou Falirou, Medical Center
    Palaio Faliro, Athens 17562, Greece
  • Athens Euroclinic
    Athens, Attiki 11521, Greece
  • General Hospital of Thessaloniki Papageorgiou
    N. Efkarpia, Thessaloniki 56403, Greece
  • Thermi Clinic
    Thermi, Thessaloniki 57001, Greece
  • Belinus Bt
    Debrecen, Hajdu-Bihar 4025, Hungary
  • Debreceni Egyetem Klinikai Kozpont Belgyogyaszati Intezet
    Debrecen, Hajdu-Bihar 4032, Hungary
  • Szent Margit Rendelőintézet Nonprofit Kft
    Budapest, 1032, Hungary
  • TRANTOR'99 Bt. Anyagcsere Centrum
    Budapest, 1213, Hungary
  • Policlinico Mater Domini
    Germaneto, Catanzaro 88100, Italy
  • Casa di Cura Multimedica-Policlinico Multispecialistico
    Sesto San Giovanni, MI 20099, Italy
  • Ospedale Luigi Sacco
    Milano, 20157, Italy
  • Policlinico Univ. Agostino Gemelli
    Roma, 00168, Italy
  • Instituto Jalisciense de Investigacion en Diabetes y Obesida
    Guadalajara, Jalisco 44600, Mexico
  • Unidad de patologia Clinica
    Guadalajara, Jalisco 44650, Mexico
  • Centro de Inv. Medica de Occidente, SC
    Zapopan, Jalisco 45116, Mexico
  • Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
    Monterrey, N.l. 64460, Mexico
  • Centro de Estudios de Investigacion Metabolicos y Cardiovasculares
    Madero, Tamaulipas 89440, Mexico
  • Centro de Endocrinologia y Nutricion del Turabo
    Caguas, 00726, Puerto Rico
  • Paola Mansilla-Letelier, MD
    Guaynabo, 00970, Puerto Rico

Showing the first 100 of 135 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Oct 2022, 23 months.

Results were first posted in Nov 2023, 1 year after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 23 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2020
First posted
Sep 3, 2020
StartActual
Oct 19, 2020
Primary completionActual
Oct 11, 2022
CompletionActual
Nov 1, 2022
Results first posted
Nov 2, 2023
Last update
Nov 2, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04537923
Responsible party
Sponsor
First posted
Sep 3, 2020
Start date
Oct 19, 2020
Primary completion
Oct 11, 2022
Completion
Nov 1, 2022
Results posted
Nov 2, 2023
Last update
Nov 2, 2023

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion